Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative…
NCT00003716 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00003716 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy |
| Official title | Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 25 |
| Start date | Mar 1, 1998 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Dec 5, 2003 |
| Last update posted | May 31, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: